Acclaro Medical has announced the approval of its flagship UltraClear® 2910 nm fiber laser by Health Canada. Acclaro Medical has also partnered with Xcite Technology, a recognised leader in aesthetic energy-based device distribution, to spearhead commercialisation efforts across Canada.

Engineered with proprietary MID IR Fiber Laser and 3DIntelliPulse™ technology, UltraClear is the world's first and only 2910 nm cold ablative fiber offering precise, customisable treatments that address superficial to deep skin concerns with minimal downtime and exceptional patient comfort. Its unique treatment modes, including 3DMIRACL® for gentle resurfacing and Laser Coring™ to help reverse a wide range of telltale signs associated with aging and gravity, set a new standard for what's possible in total skin health.

"The approval of our UltraClear in Canada as the first and only 2910 nm fiber laser marks a significant milestone in our steadfast commitment to bringing breakthrough innovation to Canadian aesthetic providers and their patients," said Helen Fang, CEO, Acclaro Medical. "Across Acclaro Medical, we are proud of our shared vision to deliver category-defining solutions for a full range of patient-friendly treatment options tailored to their needs, lifestyles and skin types," added Fang.

"UltraClear is unlike anything currently available. The 2910 nm cold ablative fiber laser combined with proprietary Laser Coring technology delivers a level of precision, depth, and patient comfort that truly redefines what's possible in skin rejuvenation," said Bill Roberts, CEO of Xcite Technologies.

As the exclusive Canadian distributor, Xcite Technologies will bring UltraClear to aesthetic clinics nationwide. With a strong track record in introducing disruptive technologies to the market, Xcite is ideally positioned to support clinical adoption and elevate standards in laser-based treatments.